{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:15:45Z","timestamp":1793232945444,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["226439"],"award-info":[{"award-number":["226439"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007076","name":"Airc Italian Foundation for Cancer Research","doi-asserted-by":"publisher","award":["IG 2015 #17326"],"award-info":[{"award-number":["IG 2015 #17326"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.tranon.2021.101240","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T06:10:36Z","timestamp":1634105436000},"page":"101240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Anti-GD2 CAR MSCs against metastatic Ewing's sarcoma"],"prefix":"10.1016","volume":"15","author":[{"given":"Giulia","family":"Golinelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Grisendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Dall'Ora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Casari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Spano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Talami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Banchelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malvina","family":"Prapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Chiavelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Rossignoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Candini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"D'Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Nasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cossarizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livio","family":"Casarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Dominici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2021.101240_bib0001","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3389\/fonc.2019.00537","article-title":"Exploiting signaling pathways and immune targets beyond the standard of care for Ewing sarcoma","volume":"9","author":"Casey","year":"2019","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.tranon.2021.101240_bib0002","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1586\/era.09.81","article-title":"Ewing's sarcoma origin: from duel to duality","volume":"9","author":"Riggi","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"10.1016\/j.tranon.2021.101240_bib0003","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev-pathol-011110-130237","article-title":"Molecular pathogenesis of ewing sarcoma: new therapeutic and transcriptional targets","volume":"7","author":"Lessnick","year":"2012","journal-title":"Ann. Rev. Pathol. Mech. Dis."},{"issue":"20","key":"10.1016\/j.tranon.2021.101240_bib0004","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2009.22.9864","article-title":"Primary disseminated multifocal ewing sarcoma: results of the euro-ewing 99 trial","volume":"28","author":"Ladenstein","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"27","key":"10.1016\/j.tranon.2021.101240_bib0005","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1200\/JCO.2014.59.5256","article-title":"Ewing sarcoma: current management and future approaches through collaboration","volume":"33","author":"Gaspar","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.tranon.2021.101240_bib0006","first-page":"173","article-title":"Metastatic Ewing's sarcoma: revisiting the \u201cevidence on the fence","volume":"38","author":"Khanna","year":"2017","journal-title":"Indian J. Med. Paediatr. Oncol. Off. J. Indian Soc. Med. Paediatr. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2021.101240_bib0007","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-018-0003-x","article-title":"Ewing sarcoma","volume":"4","author":"Gr\u00fcnewald","year":"2018","journal-title":"Nat. Rev. Dis. Primer"},{"issue":"21","key":"10.1016\/j.tranon.2021.101240_bib0008","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2007.15.7198","article-title":"Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2\/tumor necrosis factor\u2013related apoptosis-inducing ligand (rhApo2L\/TRAIL)","volume":"26","author":"Ashkenazi","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.tranon.2021.101240_bib0009","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3390\/cancers11040456","article-title":"TRAILblazing strategies for cancer treatment","volume":"11","author":"Kretz","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.tranon.2021.101240_bib0010","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrc.2017.28","article-title":"Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy","volume":"17","author":"von Karstedt","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tranon.2021.101240_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104716","article-title":"TRAIL in oncology: from recombinant TRAIL to nano- and self-targeted TRAIL-based therapies","volume":"155","author":"Dianat-Moghadam","year":"2020","journal-title":"Pharmacol Res"},{"issue":"10","key":"10.1016\/j.tranon.2021.101240_bib0012","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2174\/1389450117666160307143226","article-title":"Tumor stroma manipulation by MSC","volume":"17","author":"Grisendi","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.tranon.2021.101240_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.529921","article-title":"Arming mesenchymal stromal\/stem cells against cancer: has the time come?","volume":"11","author":"Golinelli","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.tranon.2021.101240_bib0014","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1158\/0008-5472.CAN-09-1865","article-title":"Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy","volume":"70","author":"Grisendi","year":"2010","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.tranon.2021.101240_bib0015","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1089\/hum.2014.039","article-title":"Surrounding pancreatic adenocarcinoma by killer mesenchymal stromal\/stem cells","volume":"25","author":"Golinelli","year":"2014","journal-title":"Hum. Gene. Ther."},{"issue":"3","key":"10.1016\/j.tranon.2021.101240_bib0016","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/stem.1903","article-title":"Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas: adipose MSC with TRAIL target sarcomas","volume":"33","author":"Grisendi","year":"2015","journal-title":"Stem Cells"},{"issue":"1","key":"10.1016\/j.tranon.2021.101240_bib0017","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-37433-6","article-title":"Soluble TRAIL armed human MSC as gene therapy for pancreatic cancer","volume":"9","author":"Spano","year":"2019","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.tranon.2021.101240_bib0018","doi-asserted-by":"crossref","first-page":"436","DOI":"10.7150\/thno.27576","article-title":"MSC-delivered soluble TRAIL and paclitaxel as novel combinatory treatment for pancreatic adenocarcinoma","volume":"9","author":"Rossignoli","year":"2019","journal-title":"Theranostics"},{"issue":"12","key":"10.1016\/j.tranon.2021.101240_bib0019","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1002\/ijc.30402","article-title":"TRAIL delivered by mesenchymal stromal\/stem cells counteracts tumor development in orthotopic Ewing sarcoma models: MSC-TRAIL counteract-Ewing sarcoma tumor development","volume":"139","author":"Guiho","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.tranon.2021.101240_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/732742","article-title":"MSCs: delivery routes and engraftment, cell-targeting strategies, and immune modulation","volume":"2013","author":"Kean","year":"2013","journal-title":"Stem Cells Int."},{"issue":"1","key":"10.1016\/j.tranon.2021.101240_bib0021","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000047856","article-title":"The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion","volume":"169","author":"Gao","year":"2001","journal-title":"Cells Tissues Organs"},{"issue":"2","key":"10.1016\/j.tranon.2021.101240_bib0022","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.transproceed.2006.12.019","article-title":"Stem cell transplantation: the lung barrier","volume":"39","author":"Schrepfer","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.tranon.2021.101240_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtm.2019.05.004","article-title":"Dissecting the pharmacodynamics and pharmacokinetics of MSCs to overcome limitations in their clinical translation","volume":"14","author":"Salvadori","year":"2019","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"issue":"1","key":"10.1016\/j.tranon.2021.101240_bib0024","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/sctm.17-0209","article-title":"Concise review: quantitative detection and modeling the in vivo kinetics of therapeutic mesenchymal stem\/stromal cells: detection and modeling kinetics of stem cells","volume":"7","author":"Brooks","year":"2018","journal-title":"Stem Cells Transl. Med."},{"issue":"28","key":"10.1016\/j.tranon.2021.101240_bib0025","doi-asserted-by":"crossref","first-page":"24884","DOI":"10.18632\/oncotarget.4670","article-title":"A novel anti-GD2\/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing","volume":"6","author":"Prapa","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2021.101240_bib0026","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3389\/fonc.2020.01000","article-title":"Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy","volume":"10","author":"Nazha","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.tranon.2021.101240_bib0027","first-page":"183","article-title":"Neuroectoderm-associated antigens on Ewing's sarcoma cell lines","volume":"47","author":"Lipinski","year":"1987","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.tranon.2021.101240_bib0028","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/1097-0142(19920801)70:3<633::AID-CNCR2820700315>3.0.CO;2-F","article-title":"Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas","volume":"70","author":"Chang","year":"1992","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.tranon.2021.101240_bib0029","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/bjc.2012.57","article-title":"The ganglioside antigen GD2 is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting","volume":"106","author":"Kailayangiri","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2021.101240_bib0030","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/imr.12131","article-title":"Design and development of therapies using chimeric antigen receptor-expressing T cells","volume":"257","author":"Dotti","year":"2014","journal-title":"Immunol. Rev."},{"issue":"3","key":"10.1016\/j.tranon.2021.101240_bib0031","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/bjc.2013.356","article-title":"Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging","volume":"109","author":"Liebsch","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2021.101240_bib0032","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1250050","article-title":"Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G","volume":"6","author":"Kailayangiri","year":"2017","journal-title":"Oncoimmunology"},{"issue":"5","key":"10.1016\/j.tranon.2021.101240_bib0033","doi-asserted-by":"crossref","first-page":"6536","DOI":"10.18632\/oncotarget.23815","article-title":"T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G","volume":"9","author":"Spurny","year":"2018","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.tranon.2021.101240_bib0034","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1002\/ijc.32743","article-title":"GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma","volume":"146","author":"Charan","year":"2020","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.tranon.2021.101240_bib0035","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/term.228","article-title":"Genetic modification of mesenchymal stem cells to express a single-chain antibody against EGFRvIII on the cell surface","volume":"4","author":"Balyasnikova","year":"2010","journal-title":"J. Tissue Eng. Regen. Med."},{"key":"10.1016\/j.tranon.2021.101240_bib0036","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1757-2215-3-12","article-title":"Targeting of mesenchymal stem cells to ovarian tumors via an artificial receptor","volume":"3","author":"Komarova","year":"2010","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.tranon.2021.101240_bib0037","article-title":"Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors","author":"Golinelli","year":"2018","journal-title":"Cancer Gene Ther [Internet]"},{"key":"10.1016\/j.tranon.2021.101240_bib0038","article-title":"Inducible Caspase9-mediated suicide gene for MSC-based cancer gene therapy","author":"Rossignoli","year":"2018","journal-title":"Cancer Gene. Ther."},{"issue":"7","key":"10.1016\/j.tranon.2021.101240_bib0039","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1089\/10430349950018157","article-title":"High-efficiency transduction and long-term gene expression with a murine stem cell retroviral vector encoding the green fluorescent protein in human marrow stromal cells","volume":"10","author":"Marx","year":"1999","journal-title":"Hum. Gene Ther."},{"issue":"11","key":"10.1016\/j.tranon.2021.101240_bib0040","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1016\/j.molimm.2007.01.020","article-title":"Ab1 and Ab2 antibodies IV. Dominance of VH domain in the induction of anti-idiotypic antibodies by gene gun immunization","volume":"44","author":"L\u00f3pez-Requena","year":"2007","journal-title":"Mol. Immunol."},{"issue":"1","key":"10.1016\/j.tranon.2021.101240_bib0041","article-title":"A novel 3D in vitro platform for pre-clinical investigations in drug testing","volume":"9","author":"Candini","year":"2019","journal-title":"Gene. Ther. Immunol. Sci. Rep.."},{"issue":"1","key":"10.1016\/j.tranon.2021.101240_bib0042","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41374-019-0298-6","article-title":"NSG mice as hosts for oncological precision medicine","volume":"100","author":"Maletzki","year":"2020","journal-title":"Lab Invest."},{"issue":"4","key":"10.1016\/j.tranon.2021.101240_bib0043","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.cell.2013.10.029","article-title":"Mechanisms governing metastatic dormancy and reactivation","volume":"155","author":"Giancotti","year":"2013","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.tranon.2021.101240_bib0044","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1634\/theoncologist.11-5-503","article-title":"Ewing's sarcoma family of tumors: current management","volume":"11","author":"Bernstein","year":"2006","journal-title":"Oncologist"},{"issue":"26","key":"10.1016\/j.tranon.2021.101240_bib0045","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1182\/blood-2009-05-224030","article-title":"Microenvironmental contaminations\u201d induced by fluorescent lipophilic dyes used for noninvasive in vitro and in vivo cell tracking","volume":"115","author":"Lassailly","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2021.101240_bib0046","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.2147\/OTT.S170585","article-title":"Management of recurrent Ewing sarcoma: challenges and approaches","volume":"Volume 12","author":"Van Mater","year":"2019","journal-title":"OncoTargets Ther."},{"issue":"6","key":"10.1016\/j.tranon.2021.101240_bib0047","first-page":"787","article-title":"Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers","volume":"1","author":"Grisendi","year":"2011","journal-title":"Am. J. Cancer Res."},{"issue":"8","key":"10.1016\/j.tranon.2021.101240_bib0048","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1158\/1078-0432.CCR-09-1779","article-title":"Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival","volume":"16","author":"Picarda","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.tranon.2021.101240_bib0049","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/sj.cdd.4400836","article-title":"Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis","volume":"8","author":"Kontny","year":"2001","journal-title":"Cell Death Differ."},{"issue":"16","key":"10.1016\/j.tranon.2021.101240_bib0050","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1073\/pnas.1221403110","article-title":"Modeling Ewing sarcoma tumors in vitro with 3D scaffolds","volume":"110","author":"Fong","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"12","key":"10.1016\/j.tranon.2021.101240_bib0051","doi-asserted-by":"crossref","first-page":"e80060","DOI":"10.1371\/journal.pone.0080060","article-title":"Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines","volume":"8","author":"May","year":"2013","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.tranon.2021.101240_bib0052","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/jor.1100180616","article-title":"Murine model for skeletal metastases of Ewing's sarcoma","volume":"18","author":"Scotlandi","year":"2000","journal-title":"J. Orthop. Res."},{"issue":"19","key":"10.1016\/j.tranon.2021.101240_bib0053","doi-asserted-by":"crossref","first-page":"8984","DOI":"10.1158\/0008-5472.CAN-05-0565","article-title":"Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering rna inhibits tumor growth in a murine model of metastatic Ewing's sarcoma","volume":"65","author":"Hu-Lieskovan","year":"2005","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.tranon.2021.101240_bib0054","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10585-015-9729-y","article-title":"Cadherin-11 regulates the metastasis of Ewing sarcoma cells to bone","volume":"32","author":"Hatano","year":"2015","journal-title":"Clin. Exp. Metastasis"},{"issue":"9","key":"10.1016\/j.tranon.2021.101240_bib0055","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/1878-0261.12057","article-title":"The endochondral bone protein CHM1 sustains an undifferentiated, invasive phenotype, promoting lung metastasis in Ewing sarcoma","volume":"11","author":"von Heyking","year":"2017","journal-title":"Mol. Oncol."},{"issue":"3","key":"10.1016\/j.tranon.2021.101240_bib0056","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1203\/00006450-200103000-00006","article-title":"Establishment of an in vivo model for pediatric Ewing tumors by transplantation into NOD\/scid mice","volume":"49","author":"Vormoor","year":"2001","journal-title":"Pediatr Res."},{"issue":"5","key":"10.1016\/j.tranon.2021.101240_bib0057","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1158\/1078-0432.CCR-05-1566","article-title":"Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models","volume":"12","author":"Schluep","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.tranon.2021.101240_bib0058","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1158\/1535-7163.MCT-09-0812","article-title":"ABT-869 inhibits the proliferation of ewing sarcoma cells and suppresses platelet-derived growth factor receptor and c-KIT signaling pathways","volume":"9","author":"Ikeda","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tranon.2021.101240_bib0059","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2014.00044","article-title":"Mesenchymal stromal cell dependent regression of pulmonary metastasis from Ewing's","volume":"2","author":"Hayes-Jordan","year":"2014","journal-title":"Front. Pediatr."},{"issue":"9","key":"10.1016\/j.tranon.2021.101240_bib0060","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/sctm.18-0024","article-title":"Concise review: mesenchymal stem cell-based drug delivery: the good, the bad, the ugly, and the promise: MSC-based drug delivery: good, bad, ugly, & promise","volume":"7","author":"Krueger","year":"2018","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.tranon.2021.101240_bib0061","first-page":"209","article-title":"MSC and tumors: homing, differentiation, and secretion influence therapeutic potential","volume":"130","author":"D'souza","year":"2013","journal-title":"Adv. Biochem. Eng. Biotechnol."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523321002321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523321002321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:28:16Z","timestamp":1778833696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523321002321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1936523321002321"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2021.101240","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-GD2 CAR MSCs against metastatic Ewing's sarcoma","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2021.101240","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101240"}}